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Abstract
Marrow stromal cells (MSCs) isolated from mesenchymal tissues can propagate in vitro to some extent and differentiate into
various tissue lineages to be used for cell-based therapies. Cellular senescence, which occurs readily in continual MSC
culture, leads to loss of these characteristic properties, representing one of the major limitations to achieving the potential
of MSCs. In this study, we investigated the effect of lysophosphatidic acid (LPA), a ubiquitous metabolite in membrane
phospholipid synthesis, on the senescence program of human MSCs. We show that MSCs preferentially express the LPA
receptor subtype 1, and an abrogation of the receptor engagement with the antagonistic compound Ki16425 attenuates
senescence induction in continually propagated human MSCs. This anti-aging effect of Ki16425 results in extended rounds
of cellular proliferation, increased clonogenic potential, and retained plasticity for osteogenic and adipogenic
differentiation. Expressions of p16
Ink4a, Rb, p53, and p21
Cip1, which have been associated with cellular senescence, were
all reduced in human MSCs by the pharmacological inhibition of LPA signaling. Disruption of this signaling pathway was
accompanied by morphological changes such as cell thinning and elongation as well as actin filament deformation through
decreased phosphorylation of focal adhesion kinase. Prevention of LPA receptor engagement also promoted ubiquitination-
mediated c-Myc elimination in MSCs, and consequently the entry into a quiescent state, G0 phase, of the cell cycle.
Collectively, these results highlight the potential of pharmacological intervention against LPA signaling for blunting
senescence-associated loss of function characteristic of human MSCs.
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Introduction
Stem/progenitor cells are the subject of intense investigation for
cell-based therapies [1]. In particular, marrow stromal cells (MSCs,
also referred to as mesenchymal stem cells), which can be isolated
from most mesenchymal tissues (e.g., bone marrow, fat, and blood
vessels), not only represent multilineage potential for differentiating
into several skeletal cell types such as osteoblasts and adipocytes but
also have the capacity to secrete soluble factors that can improve
repair of multiple organs such as bone, brain, heart, lung, and
pancreas and modulate the immune system [2,3,4,5,6,7,8]. MSCs
divide rapidly in culture and thus are potentially attractive for use in
developing new therapeutic approaches [2,6,7]. However, MSCs in
culture are readily observed to senesce after $25 population
doublings, a process in which they propagate slowly, decrease their
clonogenicity,andlose theirpotentialtodifferentiate[7,9,10,11,12].
The propensity for a decrease in the MSC’s potential prevents
extensive rounds of in vitro expansion for obtaining clinically
significant cell numbers and demands modification of culture
conditions to alleviate their senescence [5,7].
Lysophosphatidic acid (LPA) is an extracellular signaling
molecule that is ubiquitously produced from membrane phospho-
lipids through phospholipase A2 (PLA2)-mediated pathways
[13,14]. To date, five subtypes of rhodopsin-like receptors with
seven-transmembrane alpha helices, LPA1-LPA5, have been
reported to bind LPA and activate G proteins, thereby inducing
various biological effects on diverse cellular and organ systems
[13,14]. In MSCs, some evidence has demonstrated the expression
of LPA1-LPA4 receptors that are likely implicated in protecting
against stress-induced apoptosis and regulating migration and
differentiation [15,16,17,18,19,20].
Here, we set out to determine whether the biological activity of
LPA toward human MSCs was also associated with the
phenotypic changes that MSCs entering into a state of senescence
undergo during continuous in vitro propagation. Based on our
finding that human MSCs preferentially express the LPA1
receptor subtype, we used a synthesized isoxazole derivative
named Ki16425, 3-(4-[4-([1-(2-chlorophenyl)ethoxy]carbonyl ami-
no)-3-methyl-5-isoxazolyl] benzylsulfanyl) propanoic acid, that
antagonizes LPA binding, particularly to LPA1 and LPA3 (rank
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[21]. Treatment of human MSCs with Ki16425 promoted
quiescence in the G0-phase of the cell cycle and thus enabled
cells to avoid the entrance into senescence that occurs following an
extended period of proliferation during continuous in vitro culture.
Methods
In vitro culture of human MSCs
Primary human MSCs were obtained at passage 1 from the
Texas A&M Health Science Center for the Preparation and
Distribution of Adult Stem Cells (Temple, TX). Human MSCs
were obtained from three donors, 21-years-old female donor 1, 22-
year-old male donor 2, and 24-year-old male donor 3; MSCs from
donor 1 were used in this study unless otherwise noted. Cells were
maintained at 37uCi n5 %C O 2 using complete culture medium
consisting of minimum essential medium alpha (Invitrogen,
Carlsbad, CA) supplemented with 17% fetal bovine serum
(Nichirei, Tokyo, Japan), 100 units/ml penicillin (Invitrogen),
100 mg/ml streptomycin (Invitrogen), and 2 mM L-glutamine
(Invitrogen), unless noted otherwise. To expand human MSCs, a
frozen vial (passage 1, 10
6 cells) was quickly thawed and plated in a
150-mm dish (Corning Inc., Corning, NY) and then incubated to
exclude non-adherent (i.e., nonviable) cells. After 24 h, viable cells
were recovered with trypsin/EDTA, re-plated at a density of 60
cells/cm
2, and then cultured, with media replaced every 3 days.
After 9 days in culture (i.e., prior to their reaching confluence),
cells were harvested for passage 2 and reseeded at a density of 60
cells/cm
2. Subsequent passages were repeated under the same
conditions every 9 days for the duration of the study. Where
indicated, human MSCs at passage 2 and thereafter were cultured
in the presence of 5 mM Ki16425/0.1% DMSO or control vehicle
alone (0.1% DMSO). The number of population doublings during
a period of growth was calculated by using the formula log10(Ne/
Ns)/log102, where Ns is the number of cells seeded at the start, and
Ne is the number of cells at the end of the period.
Colony-forming unit-fibroblast (CFU-F) assay
Human MSCs were seeded into 100-mm culture dishes at 100
cells/dish. After 15 days of culture with medium replaced every 3
days, the cultures were fixed and stained with crystal violet staining
solution in methanol (Kanto Chemical, Tokyo, Japan) for 20 min
at RT. The dishes were washed with water and allowed to dry.
Colonies were counted macroscopically, and data were reported as
colony numbers per dish.
Senescence-associated b-galactosidase (SA-b-Gal) assay
Human MSC monolayers were fixed with 0.2% glutaraldehyde
for 20 minat RT,washed twice with PBS,and then stained for 24 h
at 37uC with SA-b-Gal staining solution: 4 mM K3[Fe(CN)6],
4m MK 4[Fe(CN)6], 2 mM MgCl2, and 1 mg/ml X-gal in PBS
(pH 6). Stained cells were viewed macroscopically and microscop-
ically under bright field at 1006magnification. The total SA-b-Gal
activities in the wells were also quantified with the Beta-Glo Assay
System (Promega, Madison, WI) according to the manufacturer’s
instructions. Briefly, lysates of human MSCs were prepared from
monolayers with passive lysis buffer and were then mixed with the
Beta-Glo Assay Reagent. After 30 min, a luminescent signal
proportional to the SA-b-Gal activity was measured for 2 s using
a Luminescencer PSN luminometer (ATTO, Tokyo, Japan).
Evaluation of telomere length
Mean telomere lengths of human MSCs were assessed in
genomic DNA by real-time PCR, as described elsewhere [22].
Real-time PCR was performed in a DNA Engine Opticon 2
System (Bio-Rad Laboratories, Hercules, CA) using SYBR
GreenER qPCR SuperMix Universal (Invitrogen) and two primer
pairs for telomere and 36B4 (single-copy gene): telomere, 59-
GGTTTTTGAGGGTGAGGGTGAGGGTGAGGGTGAGGG-
T-39 and 59-TCCCGACTATCCCTATCCCTATCCCTATCC-
CTATCCCTA-39; 36B4, 59-CAGCAAGTGGGAAGGTGTAA-
TCC-39 and 59-CCCATTCTATCATCAACGGGTACAA-39.
The telomere/36B4 ratio for the amount of the PCR product
was measured as proportional to the mean telomere length, and
the factor by which the telomere/36B4 ratio of the sample differed
from the mean of control samples was determined as the relative
telomere length.
Western blotting
Human MSCs were lysed in RIPA buffer containing protease
inhibitor cocktail and phosphatase inhibitor cocktail (all from
Sigma-Aldrich, St. Louis, MO). Proteins were separated by SDS-
PAGE (Novex 10% Tris-glycine) and transferred onto PVDF
using iBlot (all from Invitrogen). Membranes were then blocked
with 2.5% milk in PBS containing 0.05% Tween-20, immuno-
blotted with specific primary antibody and the relevant horserad-
ish peroxidase (HRP)-conjugated secondary antibodies (Santa
Cruz Biotechnology, Santa Cruz, CA). The signals were visualized
using the ECL detection system (GE Healthcare, Piscataway, NJ).
The primary antibodies used in this study were anti-phosphory-
lated cPLA2 (Ser505), anti-total cPLA2, anti-phosphorylated Akt
(Ser473), and anti-total Akt (all from Cell Signaling Technology,
Danvers, MA); anti-c-Myc (Santa Cruz Biotechnology); anti-Fbw7
and anti-p16
INK4a (both from Abnova, Walnut, CA); anti-Rb
(retinoblastoma-associated protein/RB1, Acris Antibodies, San
Diego, CA); anti-p53 (Thermo Fisher Scientific, Waltham, MA);
anti-phosphorylated FAK (Tyr861) and anti-p21
Cip1 (both from
Signalway Antibody, Pearland, TX); anti-total FAK (BioLegend,
San Diego, CA); and anti-b-actin (clone AC-15, Sigma-Aldrich).
Quantification of band intensity was performed using Quantity
One software (Bio-Rad Laboratories, Hercules, CA).
Reverse transcriptase–polymerase chain reaction (RT-
PCR)
Total RNA was extracted using an RNeasy Plus kit (QIAGEN,
Valencia, CA). RNA was reverse-transcribed using the Super-
Script III first-strand synthesis system (Invitrogen) to generate
cDNA. The resulting cDNA was amplified by semiquantitative
PCR using Platinum Taq DNA polymerase (Invitrogen) or by real-
time PCR as described above. All real-time PCR mRNA
expression data were normalized to glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) expression, and the factor by which the
normalized expression of the sample differed from the mean of
control or LPA1 samples was determined as the relative gene
expression. The primer pairs used in this study were as follows;
LPA1,5 9-AATCGGGGATACCATGATGAGTCTT-39 and 59-
CCAGGAGTCCAGCAGATGATAAA-39; LPA2,5 9-CGCTCA-
GCCTGGTCAAGACT-39 and 59-TTGCAGGACTCACAGC-
CTAAAC-39; LPA3,5 9-AGGACACCCATGAAGCTAATGAA-
39 and 59-GCCGTCGAGGAGCAGAAC-39; LPA4,5 9-AAAG-
ATCATGTACCCAATCACCTT-39 and 59-CTTAAACAGGG-
ACTCCATTCTGAT-39; LPA5,5 9-CTCTCCTACTACGCAC-
TGCACCACT-39 and 59-GAAGCTCTCGAAGCATAGGCG-
CA-39; Osteopontin, 59-CTAGGCATCACCTGTGCCATACC-
39 and 59-CAGTGACCAGTTCATCAGATTCATC-39; FABP4,
59-ATGGGATGGAAAATCAACCA-39 and 59-GTGGAAGTG-
ACGCCTTTCAT-39; GAPDH, 59-GAGTCAACGGATTTGG-
TCGT-39 and 59-TTGATTTTGGAGGGATCTCG-39.
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Human MSCs treated with or without Ki16425 were fixed with
4% paraformaldehyde for 30 min, washed with PBS, and
incubated for 30 min with 5 U/ml fluorescein isothiocyanate
(FITC)-conjugated phalloidin (a high-affinity filamentous actin
probe; Enzo Life Sciences, Farmingdale, NY), 5 mg/ml propidium
iodide (nuclear co-staining), and 0.1% Tween-20 in PBS. Stained
cells were viewed at 1006magnification using a BX51 fluorescent
microscopy (Olympus, Tokyo, Japan), and the cell morphology
was monitored.
Cell cycle assay
Human MSCs were collected and fixed with 80% ethanol
overnight at 4uC. Fixed cells were then resuspended in PBS
containing 0.1% bovine serum albumin and 0.25 mg/ml 7-AAD
(DNA dye; Imgenex, San Diego, CA). After incubation at 4uC for
1 h, pyronin Y (RNA dye; Sigma-Aldrich) was added to a final
concentration of 2 mg/ml, and cells were incubated for a further
1 h and then maintained at 4uC. G0 and G1 cell populations were
identified as displaying low and high RNA staining, respectively,
within the G0/G1 DNA phase by an EPICS XL cytometer with
EXPO32 ADC software (Beckman Coulter, Miami, FL).
Osteogenic and adipogenic differentiation assays
Human MSCs were seeded in six-well Collagen I Cellware
plates (BD Biosciences) with osteogenic medium (complete culture
medium, 1 nM dexamethasone, 20 mM b-glycerophosphate, and
50 mg/ml ascorbate 2-phosphate) or adipogenic medium (com-
plete culture medium, 0.5 mM dexamethasone, 0.5 mM isobutyl-
methylxanthine, and 50 mM indomethacin). Plates were incubated
for 2 (osteogenic) or 3 (adipogenic) weeks with medium
replenishment every 3 days. After the differentiation process, cell
monolayers were fixed with 10% formaldehyde for 15 min and
stained with 0.1% alizarin red S solution (osteogenesis, Wako
Chemicals, Richmond, VA) for 20 min or with 0.18% oil red O
(adipogenesis, Sigma-Aldrich) in 60% isopropanol for 20 min.
Stained cells were viewed macroscopically and microscopically
under bright field at 1006 magnification. To quantify staining
intensity, the dye remaining in each well was extracted by lysing
the cells in 0.5 ml of passive lysis buffer (Promega). The
absorbance of the solution was then measured at 570 nm using
an EMax microplate reader (Molecular Devices, Sunnyvale, CA).
Statistical analysis
All data are reported as means 6 standard error unless
otherwise stated. Statistical comparisons were performed by two-
tailed Student’s t-test. In all analyses, P,0.05 was taken to indicate
statistical significance.
Results
Senescence-associated impairment of MSC clonogenic
potential in continual culture
To ensure that the functional capacity of MSCs was reduced
during cultivation in vitro, we examined the colony-forming
efficiency, cellular senescence, and telomere length of human
MSCs with increasing cell passages (Fig. 1). The number of MSCs
capable of initiating colonies (the colony-forming unit fibroblasts,
CFU-Fs) is commonly used as a measure of differential potential
and self-renewal capacity [9]. The frequency of CFU-Fs was
markedly decreased during cell passages 2–4, although the CFU-F
numbers of passages 3 and 4 were not significantly different from
that of passage 2 (passage 3, P=0.06; passage 4, P=0.05; Fig. 1A).
The senescent state in continuous MSC cultures was assessed using
senescence-associated b-galactosidase (SA-b-Gal), an established
biomarker associated with cellular aging [23,24,25]. Human
MSCs at passages 2–4 showed a gradual increase in SA-b-Gal
activity; these activities were significantly different (passages 2–3,
P,0.01; passages 3–4, P,0.01; passages 2–4, P,0.01; Fig. 1B).
The gradual induction of cellular senescence in continuous MSC
culture was inversely correlated with telomere length; this
decreased significantly between passages 3 and 4 (P,0.05;
Fig. 1C). These data show that human MSCs during culture
under standard conditions undergo a senescent change as a
consequence of telomere shortening, accompanied by a reduction
in colony-forming efficacy.
An LPA receptor antagonist reduces MSC senescent
changes
We next investigated the role of lysophosphatidic acid signaling
in shaping the cell growth kinetics of continuously-cultured human
MSCs. Under standard culture conditions, human MSCs
exhibited a relatively constant population doubling rate for 54
days, i.e., six passages, after which they entered growth arrest, with
no appreciable increase in cumulative population doublings
(Fig. 2A). In contrast, upon addition of Ki16425, a selective
antagonist for lysophosphatidic acid receptor subtypes 1 and 3
(LPA1 and LPA3), human MSCs maintained their proliferative
potential over the period studied, and cumulative population
doublings increased at a constant rate for 108 days, i.e., 12
passages (Fig. 2A). Immunoblotting of human MSC lysates
revealed Ser505 phosphorylation and activation of cytosolic
phospholipase A2 (cPLA2), a major enzyme producing lysopho-
sphatidic acid from membrane phospholipids (Fig. 2B) [26].
Human MSCs also expressed the lysophosphatidic acid LPA1
receptor gene at much higher levels relative to LPA2, LPA3, LPA4,
and LPA5 receptor genes, as determined by real-time PCR
analysis (P,0.001 compared with all other LPA receptors,
Fig. 2C). The expression level of the LPA1 receptor gene was
stable in human MSCs cultured for up to 54 days (not shown).
These data suggest that Ki16425 facilitates extended MSC
expansion by hindering autocrine and paracrine lysophosphatidic
acid signaling mainly through the LPA1 receptor.
Expansion of somatic diploid cells is generally regulated by
replicative senescence due to telomere shortening during cell
division [23,25]. We therefore examined the impact of Ki16425
on cellular functions associated with the state of senescence.
Antagonism of lysophosphatidic acid LPA1/LPA3 receptors in
human MSC cultures resulted in a striking cellular phenotype,
with induction of clonogenic capacity with elevated CFU-F
numbers (P,0.01; Fig. 2D). Furthermore, whereas a majority
of MSCs in control cultures showed strong SA-b-Gal staining, few
of the cells treated with Ki16425 showed staining coincident with
the significantly reduced activity of SA-b-Gal (P,0.001; Fig. 2E).
The telomere length of human MSCs cultured with Ki16425 was
2.2-fold greater than that of control MSCs (P,0.005; Fig. 2F).
Similar results were achieved in human MSCs from donors of
different age (Fig. S1).
Activation of the p16
Ink4a-Rb and p53-p21
Cip1 signaling
pathways has been shown to reduce stem/progenitor-cell
frequency and function in a variety of aging tissues [27,28,29].
We therefore investigated the potential of Ki16425 to decrease
protein levels of components in these signaling cascades.
Immunoblotting of total cell lysates revealed reduced expression
of p16
Ink4a, Rb, p53, and p21
Cip1 in Ki16425-treated human
MSCs compared with that in time-point-matched control MSCs;
no apparent differences in confluency of the MSC culture were
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upward trend evident at 9–18 days was reduced by Ki16425
treatment, with the exception of Rb, in which case a downward
trend was accelerated (Fig. 2G). Taken together, these data
suggest that lysophosphatidic acid signaling through the LPA1/
LPA3 receptors is essential for regulation of the functional
properties of human MSCs. Furthermore, during continuous
propagation, LPA receptor self-activation leads to induction of
cellular senescence.
Inhibition of LPA signaling results in alterations in cell
shape and transition to a quiescent state
Morphological changes in human MSCs likely reflect cellular
function, as has been reported [30,31,32,33]. We then assessed cell
morphology by phase-contrast microscopy and found that human
MSCs adopted a thin and elongated phenotype upon treatment
with Ki16425, an LPA1/LPA3 receptor antagonist, compared with
controls (Fig. 3A). This phenotypic change correlates with
alteration of cytoskeleton content; immunostaining for filamentous
actin (F-actin) after disruption of LPA1/LPA3 receptors with
Ki16425 revealed deformation of actin filaments running through
the cell body of human MSCs when compared to the control
(Fig. 3B). As analyzed by Western blotting of cell extracts from
human MSCs, phosphorylation of focal adhesion kinase (FAK), a
key signaling event implicated in actin organization through Rho
activation, was attenuated in the hours immediately following
Ki16425 treatment (Fig. 3C) [34,35].
We next asked whether LPA receptor-selective inhibition of
human MSCs may also affect the cell-cycle state. Previous studies
have shown a link between cell shape and proliferation kinetics,
indicating the limited proliferative capacity of thin spindle-shaped
cells such as Ki16425-treated MSCs [30,32]. As anticipated, cell-
cycle analysis of human MSCs showed that Ki16425-treated cells
were significantly enriched for pyronin Y
low-staining cells in the G0
phase compared with control cells (P,0.05; Fig. 3D). Enrichment
of the G0 phase MSC population by Ki16425 suggests that in the
absence of LPA1/3 receptor-mediated signaling, human MSCs are
predisposed to exit from the cell cycle and enter a quiescent state.
To further characterize the nature of cell-cycle regulation, we
analyzed expression of the transcription factor c-Myc, a key
component of the cell-cycle transition, in human MSCs that had
been treated with Ki16425 for either 2 or 4 days and found that it
was lower at the later time point (i.e., 4 days) compared with
control cells (Fig. 3E). This reduced c-Myc level in Ki16425-
treated MSCs was accompanied by an increase in expression of
FBW7 (F-box and WD repeat domain-containing 7), a substrate
recognition component of SCF-type ubiquitin ligase that targets c-
Myc and mediates polyubiquitination for proteasomal degradation
(Fig. 3E) [36,37]. Paradoxically, the results of immunostaining
also showed that levels of phosphorylated Akt (Phospho-Akt),
Figure 1. In vitro continuous culture of human MSCs reduced their clonogenic capacity with cellular senescence over three
consecutive passages at passages 2, 3, and 4. A. CFU-F assay. CFU-F colonies from human MSCs (passages 2, 3, and 4; 100 cells) were counted
after culture for 15 days. On the right side are shown representative CFU-F colonies stained with crystal violet. B. SA-b-Gal assay. The total SA-b-Gal
activities of human MSCs (passages 2, 3, and 4) were quantified in the wells of six-well plates as the luminescent intensity (relative luminescence units,
RLU) that was generated due to the cleavage of a luciferin-galactoside substrate. C. Telomere measurement. Telomere lengths were determined in
human MSCs (passages 2, 3, and 4) by real-time PCR and quantified relative to the mean of passage 2. For all panels, the data are presented as the
means 6 standard error (n=3).
doi:10.1371/journal.pone.0032185.g001
Targeting LPA Signaling Retards Senescence of MSCs
PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e32185Figure 2. Decreased self-renewal capacity associated with senescence was prevented in human MSCs following treatment with
Ki16425, an LPA1/LPA3 antagonist. A. Growth kinetics during serial passage. Human MSCs at passage 2 (8.1 population doublings) were serially
passaged every 9 days in the presence or absence of Ki16425. Cumulative population doublings are presented as the means of duplicates. B. Western
blotting analysis of total and phosphorylated cPLA2 in human MSCs at passage 2. C. Real-time PCR analysis of LPA receptor gene expression in
human MSCs at passage 2. Levels of mRNA were quantified relative to the mean of LPA1 samples. D. CFU-F assay. Human MSCs at passage 2 were
cultured in the presence or absence of Ki16425 for two additional passages (27 days). CFU-F colonies initiated from the treated cells (passage 5, 100
cells) were counted after 15 days of normal culture. On the right side are shown representative CFU-F colonies stained with crystal violet. E. SA-b-Gal
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(glycogen synthase kinase 3) and/or activating eIF4E (eukaryotic
initiation factor 4E), became gradually elevated in human MSCs
upon Ki16425 treatment compared with time-point-matched
controls (Fig. 3E) [38,39]. Besides c-Myc accumulation, a variety
of signaling molecules downstream of Akt have been reported to
promote cell survival, growth, and proliferation, suggesting that
disruption of LPA1/LPA3 receptor engagement coordinates
several signal pathways in MSCs and induces them to enter a
cell-cycle state of quiescence without impairing cell growth
kinetics.
Absence of LPA receptor engagement potentiates MSC
differentiation capacity
To examine whether the differentiation potential of the human
MSCs was altered when LPA1/LPA3 receptor-mediated signaling
was crippled, we undertook a study assaying differentiation into
osteoblasts and adipocytes. After osteogenic culture, alizarin red S
staining revealed that Ki16425-treated MSCs had calcium
phosphate mineralization to a higher degree than did control
MSCs, and there was also a significant difference in the amount of
extracted dye (P,0.005; Fig. 4A). On the other hand, when
subjected to adipogenic differentiation, Ki16425-treated MSCs
exhibited a higher level of oil red O staining (an indicator of
intracellular lipid accumulation), with a concomitant increase in
the quantity of dye extracted (P,0.005; Fig. 4B). This greater
potential to differentiate into osteoblasts and adipocytes is further
supported by the finding that under each differentiation-inducing
culture, the proper gene expression was enhanced in Ki16425-
treated MSCs. As determined by real-time PCR, the expression of
genes encoding osteopontin or fatty acid-binding protein 4
(FABP4) was significantly upregulated in human MSCs that had
been exposed to Ki16425 before osteogenic or adipogenic
differentiation, respectively (osteopontin, P,0.001, Fig. 4C;
FABP4, P,0.001, Fig. 4D).
Discussion
In this study, we demonstrated that LPA plays a prominent role
in the induction of cellular senescence that human MSCs undergo
through continual propagation, as evidenced by attenuation of
senescence-associated changes in human MSCs treated with
Ki16425, an LPA receptor engagement antagonist. The
Ki16425 treatment of human MSCs reduced both SA-b-Gal
accumulation and telomere shortening through the inactivation
the p16
Ink4a-Rb and p53-p21
Cip1 signaling pathways, resulting in
extensive propagation with retained clonogenic and differentiation
potential. Besides the functional relevance, the anti-aging effects of
the Ki16425 treatment were accompanied by morphological
changes that were caused by dephosphorylation of focal adhesion
kinase via preventing polymerization of actin filaments. LPA-
associated processes also involve cell-cycle regulation in human
MSCs, and therefore the targeting treatment increased quiescent
MSCs in the G0 phase of the cell cycle as a consequence of
promoting ubiquitin-mediated c-Myc degradation.
MSCs possess the potential not only to differentiate into a
variety of mesenchymal lineages such as osteoblasts and
adipocytes, but also to secrete both defined and as-yet-undefined
paracrine soluble factors that may ameliorate several clinical
disorders including myocardial infarction, diabetes, sepsis,
hepatic failure, acute renal failure, and acute lung injury
[4,6,40,41,42,43,44]. This property makes MSCs attractive for
the cell-based therapeutic approach because they can be easily
isolated from human mesenchymal tissues and subsequently
expanded in vitro for administration [6,40,41,42]. However,
previous studies have shown that human MSCs tend to enter a
state of senescence under standard culture conditions as early as
25 population doublings, which poses a major stumbling block to
in vitro MSC propagation while retaining therapeutic potential
[7,9,10,45,46]. In this study, MSCs cultured in the standard
conditions also exhibited signs of senescence at early passage and
thereafter entered a state of arrested growth, probably due to the
disparity between cell senescence and the replicative capacity
[47].
Cellular senescence conceptually consists of two categories,
replicative and stress-induced [23,25,48]. Whereas replicative
senescence is attributed to critical attrition of the telomere that
counts the number of cell divisions by shortening its length with
every division, stress-induced senescence is viewed as occurring
without telomere shortening in normal cells exposed to various
physical stresses, such as DNA-damaging agents, oxidative stress,
and metabolic perturbations [23,25,49,50]. The conditions that
induce these two responses cannot always be distinguished. For
example, some types of normal cells exhibit replicative
senescence due to the cumulative stress of certain culture
conditions that are physiologically stressful to the cells [23]. This
knowledge leads us to attempt modified culture conditions in
which human MSCs undergo senescence-retarding expansion.
Several pieces of evidence in the present study substantiate that
this effort is valid. Supplement of standard culture conditions
with an LPA receptor antagonist prevented telomere shortening
of human MSCs and consequently brought about extensive
expansion of MSCs, with preservation of their CFU-F-forming
and differentiation capacity.
Over the past few years great interest has been shown in LPA, a
water-soluble phospholipid, not only because it is an inert
metabolite in the biosynthesis of membrane phospholipids but
also because it is an important signaling molecule [13,14,51].
Cellular responses altered by LPA include a diverse range of
mammalian cell processes that are mediated by five G protein-
coupled receptors, LPA1–5 [13,14]. Human MSCs have been
reported to express the LPA1, LPA2, LPA3, and LPA4 receptors,
and we have shown that LPA1 expression is markedly higher than
that of the others [16,20]. This observation suggests that the
functional role of Ki16425, a selective antagonist for both LPA1
and LPA3 receptors, is probably mediated by disturbance of LPA1-
receptor engagement on human MSCs.
LPA receptors have broad expression patterns that allow LPA to
exert biological effects on many different target tissues [13,14].
Although some of the mechanisms regulating stem-cell functions
are now beginning to be clarified, much remains unknown [14]. In
assay. The total SA-b-Gal activities of Ki16425- and vehicle-treated human MSCs were quantified in the wells of six-well plates as the luminescent
intensity (relative luminescence units, RLU). On the right side are shown representative human MSCs stained for SA-b-Gal. Scale bars in inset boxes,
200 mm. F. Telomere measurement. Telomere lengths were determined in Ki16425- and vehicle-treated human MSCs by real-time PCR and quantified
relative to the mean of vehicle controls. G. Western blotting analysis of cell-cycle components. Human MSCs at passage 2 were cultured in the
presence or absence of Ki16425 for the indicated days prior to cell lysis. Fold-change represents decrease in band intensity of Ki16425 treatment for
18 days compared with a control treatment for the same period of time. For panels C, D, E, and F, the data are presented as the means 6 standard
error (n=3).
doi:10.1371/journal.pone.0032185.g002
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regulation have been published. First, Jaganathan, et al. and Lee,
et al. showed that LPA treatment of human MSCs activated
intracellular Rho and increased actin stress fibers, consistent with
our finding that repression of LPA signaling by Ki16425 decreased
actin polymerization of human MSCs probably due to Rho
inactivation [16,17]. Second, Chen, et al. demonstrated that LPA
protected rat MSCs against apoptosis induced by cellular stresses
such as hypoxia, serum deprivation, and ischemia. Contrary to
their findings, the present study indicates that targeting endoge-
nous LPA signaling through autocrine and/or paracrine mecha-
nisms extends the lifespan of human MSCs over 112 population
doublings rather than promoting apoptosis, at least under steady-
state culture conditions [15,18,19]. Third, Liu, et al. pointed out
that inhibition of LPA signaling with Ki16425 during osteogenic
differentiation abrogated the osteogenesis of human MSCs over-
expressing telomerase. This is contrary to our finding that
pretreatment with Ki16425 induced osteogenesis of human MSCs
Figure 3. LPA1/3 inhibition of human MSCs reduced actin polymerization and increased cell-cycle quiescence. A, B. Phenotypic
characteristics of human MSCs treated with Ki16425 or vehicle alone for 48 h after plating. Shown are phase-contrast images (panel A) and
fluorescent images in which filamentous actin (F-actin) was visualized with green phalloidin-FITC staining and nuclei were stained with red propidium
iodide (panel B). Scale bars, 200 mm. C. Western blotting analysis to evaluate the phosphorylation and activation status of focal adhesion kinase
(FAK). D. Cell-cycle analysis. Human MSCs treated with Ki16425 or vehicle alone for 72 h were fixed and then stained for DNA and RNA with 7-AAD
and pyronin Y, respectively. Their cell-cycle status was assessed based on their DNA and RNA content by flow cytometry. A representative of three
experiments is shown on the left side, and the bar graph summarizes the results of the G0 proportion on the right side. The data are presented as the
means 6 standard error (n=3). E. Western blotting analysis of signaling molecules associated with the Akt pathway. For panels C and E, human
MSCs were cultured in the presence or absence of Ki16425 for the indicated times prior to cell lysis.
doi:10.1371/journal.pone.0032185.g003
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over-expression of telomerase in human MSCs or LPA signaling
status under osteogenic culture conditions. Finally, Mansell, et al.
treated human MSCs in vitro with albumin-bound LPA and
vitamin D3, finding that the treatment co-operatively promoted
the osteoblastogenesis [52]. Understanding the precise role of LPA
signaling in MSC osteogenic differentiation as well as the
relevance of these in vitro observations to in vivo cellular function
thus awaits further studies.
Supporting Information
Figure S1 Prevention of decreased self-renewal capacity
associated with senescence was also observed in
Ki16425-treated human MSCs from different donors.
A., B. CFU-F assay. Human MSCs from donor 2 (A) or donor 3
(B) at passage 2 were cultured in the presence or absence of
Ki16425 for two additional passages (27 days). CFU-F colonies
initiated from the treated cells (passage 5, 100 cells) were counted
after 15 days of normal culture. C., D. SA-b-Gal assay. The total
SA-b-Gal activities of Ki16425- and vehicle-treated human MSCs
from donor 2 (C) or donor 3 (D) were quantified in the wells of six-
well plates as the luminescent intensity (relative luminescence
units, RLU). E., F. Telomere measurement. Telomere lengths
were determined in Ki16425- and vehicle-treated human MSCs
from donor 2 (E) or donor 3 (F) by real-time PCR and quantified
relative to the mean of vehicle controls. For all panels, the data are
presented as the means 6 standard error (n=3). P values
compared to controls were indicated.
(TIF)
Figure 4. Maintenance of osteogenic and adipogenic potency in human MSCs was promoted through impaired LPA1/3 signaling.
Human MSCs were cultured for 6 days in the presence of Ki16425 or vehicle alone and subjected to osteogenic (panels A and C) or adipogenic
(panels B and D) induction for 2 or 3 weeks, respectively. A. Osteogenic cultures were stained with alizarin red S. B. Adipogenic cultures were stained
with oil red O. For panels A and B, the staining was quantified as absorbance at OD570 per well (right side). Scale bars in inset boxes (left side),
200 mm. C. Osteopontin gene expression in osteogenic cultures. D. Fatty acid-binding protein 4 (FABP4) gene expression in adipogenic cultures. For
panels C and D, mRNA levels were determined by real-time PCR and quantified relative to the mean of vehicle controls. For all panels, the data are
presented as the means 6 standard error (n=3).
doi:10.1371/journal.pone.0032185.g004
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